EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-IL-17 and Anti-IL-23 Therapies Modulate Serum Biomarkers of Intestinal Dysbiosis and Oxidative Stress Linked to Cardiovascular Risk in Patients with Psoriasis

Giuseppe Annunziata iD, Emanuele Scala iD, Laura Mercurio, Luca Sanna, Anna Dattolo iD, Gianluca Pagnanelli, Maria Grazia Lolli iD, Roberta Belli, Gaia Moretta, Silvia Savastano iD, Giovanna Muscogiuri iD, Maria Maisto iD und 6 weitere

Life · 03.11.2025 · 15 (11) · 1703

DOI: 10.3390/life15111703 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life, online erschienen am 03.11.2025. Verfasst von Giuseppe Annunziata und 17 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Psicologia e Scienze della Salute, Università Telematica Pegaso, Via Porzio, Centro Direzionale Isola F2, 80143 Naples, Italy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union-Next Generation EU, European Union—Next Generation EU, Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis is a chronic inflammatory skin disease whose pathogenesis involves not only cutaneous inflammation but also intestinal dysbiosis and oxidative stress (OxS). Monoclonal antibodies targeting interleukin (IL)-17 and IL-23 have demonstrated significant immunomodulatory effects; however, their impact on systemic parameters requires further investigation. We conducted a study on 33 patients with plaque psoriasis treated with anti-IL-17 or anti-IL-23 monoclonal antibodies. Dermatological parameters (Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI)), biomarkers of intestinal dysbiosis (trimethylamine-N-oxide (TMAO)) and OxS (reactive oxygen metabolites (d-ROMs) and oxidized LDL (oxLDL)) were evaluated. Anthropometric, metabolic, and adipose-derived hormonal parameters (adipokines) were also monitored. After 16 weeks of therapy, significant improvements were observed in PASI and DLQI scores (p < 0.001). TMAO levels were significantly reduced (p = 0.02), as were d-ROMs and oxLDL (p < 0.001). No significant changes were found in weight, body mass index, lipid profile, or adipokine levels (visfatin, leptin and adiponectin). Our data indicate that monoclonal antibody therapy not only improves psoriasis severity but also exerts beneficial effects on systemic biomarkers of dysbiosis and OxS, independent of metabolic or hormonal changes. These findings suggest a systemic mechanism of action, supporting a multifactorial therapeutic effect with potential implications for the prevention of cardiovascular risk.

Schlagwörter

Stichwörter der Autor:innen

TMAOd-ROMsgut-skin axisimmune-cardio-metabolic modulationinflammationoxLDLpsoriasis

Autor:innen und Institutionen

  • Dipartimento di Psicologia e Scienze della Salute, Università Telematica Pegaso, Via Porzio, Centro Direzionale Isola F2, 80143 Naples, Italy.
  • Laboratory of Experimental Immunology, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, 00167 Rome, Italy.
  • Department of Dermatology, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, 00167 Rome, Italy.
  • Unità di Endocrinologia, Diabetologia ed Andrologia, Dipartimento di Medicina Clinica e Chirurgia, University of Naples Federico II, 80131 Naples, Italy.
  • Centro Italiano per la Cura e il Benessere del Paziente con Obesità (C.I.B.O), University of Naples Federico II, 80131 Naples, Italy.
  • Cattedra Unesco "Educazione Alla Salute E Allo Sviluppo Sostenibile", University of Naples Federico II, 80131 Naples, Italy.

ORCID-Profile: Giuseppe Annunziata, Emanuele Scala, Anna Dattolo, Maria Grazia Lolli, Silvia Savastano, Giovanna Muscogiuri, Maria Maisto, Roberto Ciampaglia, Vincenzo Piccolo, Gian Carlo Tenore, Cristina Albanesi, Stefania Madonna, Luigi Barrea

Förderung

  • European Union-Next Generation EU
  • European Union—Next Generation EU
  • Italian Ministry of Health

Zitieren

APA

Annunziata, G., Scala, E., Mercurio, L., Sanna, L., Dattolo, A., Pagnanelli, G., Lolli, M. G., Belli, R., Moretta, G., Savastano, S., Muscogiuri, G., Maisto, M., Ciampaglia, R., Piccolo, V., Tenore, G. C., Albanesi, C., Madonna, S., & Barrea, L. (2025). Anti-IL-17 and Anti-IL-23 Therapies Modulate Serum Biomarkers of Intestinal Dysbiosis and Oxidative Stress Linked to Cardiovascular Risk in Patients with Psoriasis. Life, 15(11), 1703. https://doi.org/10.3390/life15111703

Vancouver

Annunziata G, Scala E, Mercurio L, Sanna L, Dattolo A, Pagnanelli G, et al. Anti-IL-17 and Anti-IL-23 Therapies Modulate Serum Biomarkers of Intestinal Dysbiosis and Oxidative Stress Linked to Cardiovascular Risk in Patients with Psoriasis. Life. 2025;15(11):1703. doi:10.3390/life15111703

BibTeX
@article{Annunziata2025,
  author = {Annunziata, Giuseppe and Scala, Emanuele and Mercurio, Laura and Sanna, Luca and Dattolo, Anna and Pagnanelli, Gianluca and Lolli, Maria Grazia and Belli, Roberta and Moretta, Gaia and Savastano, Silvia and Muscogiuri, Giovanna and Maisto, Maria and Ciampaglia, Roberto and Piccolo, Vincenzo and Tenore, Gian Carlo and Albanesi, Cristina and Madonna, Stefania and Barrea, Luigi},
  title = {Anti-IL-17 and Anti-IL-23 Therapies Modulate Serum Biomarkers of Intestinal Dysbiosis and Oxidative Stress Linked to Cardiovascular Risk in Patients with Psoriasis},
  journal = {Life},
  year = {2025},
  volume = {15},
  number = {11},
  pages = {1703},
  doi = {10.3390/life15111703}
}
Kostenlos starten →